The role of hepatitis E virus infection in adult Americans with acute liver failure

Acute hepatitis E virus (HEV) infection is a leading cause of acute liver failure (ALF) in many developing countries, yet rarely identified in Western countries. Given that antibody testing for HEV infection is not routinely obtained, we hypothesized that HEV‐related ALF might be present and unrecog...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 64; no. 6; pp. 1870 - 1880
Main Authors Fontana, Robert John, Engle, Ronald E., Scaglione, Steven, Araya, Victor, Shaikh, Obaid, Tillman, Holly, Attar, Nahid, Purcell, Robert H., Lee, William M.
Format Journal Article
LanguageEnglish
Published United States Wolters Kluwer Health, Inc 01.12.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Acute hepatitis E virus (HEV) infection is a leading cause of acute liver failure (ALF) in many developing countries, yet rarely identified in Western countries. Given that antibody testing for HEV infection is not routinely obtained, we hypothesized that HEV‐related ALF might be present and unrecognized in North American ALF patients. Serum samples of 681 adults enrolled in the U.S. Acute Liver Failure Study Group were tested for anti‐HEV immunoglobulin (Ig) M and anti‐HEV IgG levels. Subjects with a detectable anti‐HEV IgM also underwent testing for HEV RNA. Mean patient age was 41.8 years, 32.9% were male, and ALF etiologies included acetaminophen (APAP) hepatotoxicity (29%), indeterminate ALF (23%), idiosyncratic drug‐induced liver injury DILI (22%), acute hepatitis B virus infection (12%), autoimmune hepatitis (12%), and pregnancy‐related ALF (2%). Three men ages 36, 39, and 70 demonstrated repeatedly detectable anti‐HEV IgM, but all were HEV‐RNA negative and had other putative diagnoses. The latter 2 subjects died within 3 and 11 days of enrollment whereas the 36‐year‐old underwent emergency liver transplantation on study day 2. At admission, 294 (43.4%) of the ALF patients were anti‐HEV IgG positive with the seroprevalence being highest in those from the Midwest (50%) and lowest in those from the Southeast (28%). Anti‐HEV IgG+ subjects were significantly older, less likely to have APAP overdose, and had a lower overall 3‐week survival compared to anti‐HEV IgG‐ subjects (63% vs. 70%; P = 0.018). Conclusion: Acute HEV infection is very rare in adult Americans with ALF (i.e., 0.4%) and could not be implicated in any indeterminate, autoimmune, or pregnancy‐related ALF cases. Past exposure to HEV with detectable anti‐HEV IgG was significantly more common in the ALF patients compared to the general U.S. population. (Hepatology 2016;64:1870‐1880)
Bibliography:Potential conflict of interest: Dr. Araya advises for and is on the speakers' bureau for Merck, AbbVie, and Gilead. He received grants from Intercept and Johnson & Johnson. Dr. Fontana received grants from Bristol‐Myers Squibb, Janssen, and Gilead. Dr. Lee consults for Lilly, Novartis, and Sanofi. He received grants from Bristol‐Myers Squibb, Merck, Gilead, and Conatus.
See Editorial on Page 1837
We gratefully acknowledge the support provided by the members of The Acute Liver Failure Study Group. This study was funded by the National Institute of Diabetes, Digestive and Kidney Diseases (DK U‐01‐58369). Additional funding provided by the Tips Fund of Northwestern Medical Foundation and the Jeanne Roberts and Rollin and Mary Ella King Funds of the Southwestern Medical Foundation. This work was supported, in part, by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0270-9139
1527-3350
DOI:10.1002/hep.28649